Dicerna Pharmaceuticals Inc (DRNA) Fundamental Analysis & Valuation

NASDAQ:DRNA

Current stock price

38.22
+0.22 (+0.58%)
At close:
38.24
+0.02 (+0.05%)
After Hours:

This DRNA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. DRNA Profitability Analysis

1.1 Basic Checks

  • In the past year DRNA has reported negative net income.
DRNA Yearly Net Income VS EBIT VS OCF VS FCFDRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 0 100M -100M

1.2 Ratios

Industry RankSector Rank
ROA -16.12%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRNA Yearly ROA, ROE, ROICDRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 -50 -100

1.3 Margins

  • The Operating Margin and Gross Margin are not available for DRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -64.53%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRNA Yearly Profit, Operating, Gross MarginsDRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DRNA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, DRNA has more shares outstanding
  • There is no outstanding debt for DRNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DRNA Yearly Shares OutstandingDRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 20M 40M 60M
DRNA Yearly Total Debt VS Total AssetsDRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 200M 400M 600M

2.2 Solvency

  • DRNA has an Altman-Z score of 1.63. This is a bad value and indicates that DRNA is not financially healthy and even has some risk of bankruptcy.
  • There is no outstanding debt for DRNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.63
ROIC/WACCN/A
WACCN/A
DRNA Yearly LT Debt VS Equity VS FCFDRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 50M 100M 150M 200M

2.3 Liquidity

  • DRNA has a Current Ratio of 2.46. This indicates that DRNA is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 2.46 indicates that DRNA has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.46
Quick Ratio 2.46
DRNA Yearly Current Assets VS Current LiabilitesDRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. DRNA Growth Analysis

3.1 Past

  • DRNA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.24%.
  • Looking at the last year, DRNA shows a very strong growth in Revenue. The Revenue has grown by 47.85%.
  • Measured over the past years, DRNA shows a very strong growth in Revenue. The Revenue has been growing by 282.76% on average per year.
EPS 1Y (TTM)-1.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
Revenue 1Y (TTM)47.85%
Revenue growth 3Y447.7%
Revenue growth 5Y282.76%
Sales Q2Q%28.79%

3.2 Future

  • The Earnings Per Share is expected to grow by 0.58% on average over the next years.
  • Based on estimates for the next years, DRNA will show a decrease in Revenue. The Revenue will decrease by -2.70% on average per year.
EPS Next Y-13.03%
EPS Next 2Y-15.97%
EPS Next 3Y-20.83%
EPS Next 5Y0.58%
Revenue Next Year-6.12%
Revenue Next 2Y2.93%
Revenue Next 3Y-3.27%
Revenue Next 5Y-2.7%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DRNA Yearly Revenue VS EstimatesDRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
DRNA Yearly EPS VS EstimatesDRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. DRNA Valuation Analysis

4.1 Price/Earnings Ratio

  • DRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRNA Price Earnings VS Forward Price EarningsDRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -20.61
DRNA Per share dataDRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • DRNA's earnings are expected to decrease with -20.83% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.97%
EPS Next 3Y-20.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DRNA Dividend Analysis

5.1 Amount

  • No dividends for DRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

DRNA Fundamentals: All Metrics, Ratios and Statistics

Dicerna Pharmaceuticals Inc

NASDAQ:DRNA (12/27/2021, 8:42:47 PM)

After market: 38.24 +0.02 (+0.05%)

38.22

+0.22 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)03-04
Inst Owners0.69%
Inst Owner Change0%
Ins Owners4.73%
Ins Owner Change0%
Market Cap2.97B
Revenue(TTM)192.85M
Net Income(TTM)-124.45M
Analysts71.43
Price Target37.16 (-2.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.41
P/FCF N/A
P/OCF N/A
P/B 27.6
P/tB N/A
EV/EBITDA -20.61
EPS(TTM)-1.63
EYN/A
EPS(NY)-2.04
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.48
BVpS1.38
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -64.53%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.46
Quick Ratio 2.46
Altman-Z 1.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
EPS Next Y-13.03%
EPS Next 2Y-15.97%
EPS Next 3Y-20.83%
EPS Next 5Y0.58%
Revenue 1Y (TTM)47.85%
Revenue growth 3Y447.7%
Revenue growth 5Y282.76%
Sales Q2Q%28.79%
Revenue Next Year-6.12%
Revenue Next 2Y2.93%
Revenue Next 3Y-3.27%
Revenue Next 5Y-2.7%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Dicerna Pharmaceuticals Inc / DRNA Fundamental Analysis FAQ

What is the fundamental rating for DRNA stock?

ChartMill assigns a fundamental rating of 3 / 10 to DRNA.


Can you provide the valuation status for Dicerna Pharmaceuticals Inc?

ChartMill assigns a valuation rating of 0 / 10 to Dicerna Pharmaceuticals Inc (DRNA). This can be considered as Overvalued.


Can you provide the profitability details for Dicerna Pharmaceuticals Inc?

Dicerna Pharmaceuticals Inc (DRNA) has a profitability rating of 4 / 10.


Can you provide the financial health for DRNA stock?

The financial health rating of Dicerna Pharmaceuticals Inc (DRNA) is 4 / 10.


What is the earnings growth outlook for Dicerna Pharmaceuticals Inc?

The Earnings per Share (EPS) of Dicerna Pharmaceuticals Inc (DRNA) is expected to decline by -13.03% in the next year.